Roland Magnusson/iStock Editorial via Getty Images
- BenevolentAI (OTC:BAIVF) Tuesday said that AstraZeneca (NASDAQ:AZN) has added a novel target for systemic lupus erythematosus to its discovery portfolio through its collaboration with the company.
- This is the second target to be selected this year from the extended collaboration with AstraZeneca (AZN), highlighting continued positive progress in the field of target identification, BenevolentAI (OTC:BAIVF) added.
- BenevolentAI’s collaboration with AstraZeneca began in 2019 in idiopathic pulmonary fibrosis and chronic kidney disease, with the collaboration expanded in January 2022 to include heart failure and SLE.
- SLE, or lupus, is a chronic autoimmune disease where the immune system mistakenly identifies the body’s own tissues as foreign.
- Source: Press Release